Caucasus Peace Dividend
This carefully selected group of stocks captures the economic opportunity created by the historic peace deal between Azerbaijan and Armenia. Handpicked by professional analysts, these companies are positioned to benefit from the new wave of trade, energy development, and infrastructure projects in a region moving from conflict to cooperation.
Your Basket's Financial Footprint
This basket's total market capitalisation is 134,939.157 and is heavily anchored by several large-cap holdings, giving it a generally stable profile.
- Large-cap dominance generally implies lower volatility and performance closely tracking broader, established-market trends.
- Consider this basket as a core, diversified holding rather than a speculative, high-growth allocation.
- Expect steady, long-term value creation rather than rapid, short-term gains; returns are not guaranteed.
TKC: $5.08B
ROAD: $6.85B
FIP: $685.92M
- Other
About This Group of Stocks
Our Expert Thinking
The landmark UAE-brokered peace accord between Azerbaijan and Armenia transforms the South Caucasus from a conflict zone into an investment opportunity. This diplomatic breakthrough opens critical trade and energy corridors between Europe and Asia, creating substantial economic growth potential in a strategically important region.
What You Need to Know
This investment theme focuses on companies positioned to benefit from large-scale reconstruction and development. The stocks span multiple sectors including infrastructure, telecommunications, energy, and construction, offering exposure to the entire value chain of economic revitalization in the South Caucasus.
Why These Stocks
These companies were selected for their direct involvement in nation-building activities that will flourish under newfound stability. From Turkish firms with regional ties to global infrastructure leaders, each is strategically positioned to capitalize on increased investment, reconstruction efforts, and new trade routes.
Why You'll Want to Watch These Stocks
First Movers Win Big
Companies establishing early positions in the post-conflict Caucasus could see exceptional growth as they help rebuild critical infrastructure and secure long-term contracts in energy, transport, and communications.
Historic Trade Route Revival
The reopening of ancient trade corridors between Europe and Asia through the South Caucasus creates immense opportunities for logistics, transportation, and energy companies that few investors have noticed yet.
Peace Pays Dividends
History shows that regions transitioning from conflict to peace often experience rapid economic growth. This carefully selected group of stocks offers exposure to the "peace dividend" that typically follows diplomatic breakthroughs.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Global Infrastructure Partners: UAE Exposure Risks
The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.
UAE Infrastructure Global Suppliers Breakdown
As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.
Antiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.